Safety, tolerability, and efficacy of brivaracetam as adjunctive therapy in patients with focal seizures, generalized onset seizures, or Unverricht-Lundborg disease: An open-label, long-term follow-up trial.
- DOI
- 10.1016/j.eplepsyres.2020.106526
- Published
- 2021 Feb
- Container
- Epilepsy research
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.eplepsyres.2020.106526,
title = {Safety, tolerability, and efficacy of brivaracetam as adjunctive therapy in patients with focal seizures, generalized onset seizures, or Unverricht-Lundborg disease: An open-label, long-term follow-up trial.},
author = {Ben-Menachem E and Baulac M and Hong SB and Cleveland JM and Reichel C and Schulz AL and Wagener G and Brandt C},
year = {2021},
journal = {Epilepsy research},
doi = {10.1016/j.eplepsyres.2020.106526},
url = {https://doi.org/10.1016/j.eplepsyres.2020.106526}
}RIS
TY - JOUR TI - Safety, tolerability, and efficacy of brivaracetam as adjunctive therapy in patients with focal seizures, generalized onset seizures, or Unverricht-Lundborg disease: An open-label, long-term follow-up trial. AU - Ben-Menachem E AU - Baulac M AU - Hong SB AU - Cleveland JM AU - Reichel C AU - Schulz AL AU - Wagener G AU - Brandt C PY - 2021 JO - Epilepsy research DO - 10.1016/j.eplepsyres.2020.106526 UR - https://doi.org/10.1016/j.eplepsyres.2020.106526 ER -
APA
E, B., M, B., SB, H., JM, C., C, R., AL, S., G, W., & C, B. (2021). Safety, tolerability, and efficacy of brivaracetam as adjunctive therapy in patients with focal seizures, generalized onset seizures, or Unverricht-Lundborg disease: An open-label, long-term follow-up trial.. Epilepsy research. https://doi.org/10.1016/j.eplepsyres.2020.106526
Source records
- pubmed · retrieved 2026-09-27T00:19:50.331Z